Table 3 Published phase 1/2 studies of olaratumab
From: PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
Author | Phase | N | Diagnosis | ORR | CBR | PFS | OS |
|---|---|---|---|---|---|---|---|
Chiorean [69] | 1 | 19 | Solid tumors | 0 | NA | NA | NA |
Doi [68] | 1 | 16 | Solid tumors | 0 | NA | NA | NA |
Tap [70] | 1b | 15 | Soft tissue sarcoma | NA | NA | NA | NA |
Tap [70] | 2 | 129 | Soft tissue sarcoma | Olaratumab+ ADM 18.2% ADM alone 11.9% | NA | 6.6 months 4.1 months | 26.5 14.7 |
Wagner [25] | 2 | 21 | GIST | PDGFR-a mutation(+) PDGFR-a mutation(−) | 50.0 14.3 | 32.1 weeks 6.1 weeks | NR 24.9 weeks |
Gerber [23] | 2 | 131 | NSCLC | olaratumab+ P/C P/C | NA | 4.4 months 4.4 months | 11.8 months 11.5 months |